Investment Research Analysts Opinion: Cytori Therapeutics, Inc. (CYTX), Maxwell Technologies, Inc. (MXWL)

Cytori Therapeutics, Inc. (NASDAQ:CYTX) tinted loss of -8.82% (-0.03 points) to US$0.33. The volume of 0.26 Million shares climbed down over an trading activity of 591.81 Million shares. EPS ratio determined by looking at last 12 month figures is -3.9. Over the same time span, the stock marked US$5.4 as its best level and the lowest price reached was US$0.29. The corporation has a market cap of US$4.33 Million.

Cytori Therapeutics, Inc. (NASDAQ:CYTX)’s earnings per share has been growing at a 36.9 percent rate over the past 5 year when average revenue increase was noted as -15.1 percent. The return on equity ratio or ROE stands at -261.3 percent while most common profitability ratio return on investment (ROI) was -77.8 percent. The company’s institutional ownership is monitored at 5.9 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 59.2 percent gross margin.

Maxwell Technologies, Inc. (NASDAQ:MXWL) is worth US$100.39 Million and has recently fallen -12.06% to US$2.26. The latest exchange of 0.35 Million shares is below its average trading activity of 322.01 Million shares. The day began at US$2.56 but the price moved to US$2.22 at one point during the trading and finally capitulating to a session high of US$2.57. The stock tapped a 52-week high of US$6.27 while the mean 12-month price target for the shares is US$4.69.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0.9, and a price to sales ratio of 0.82. For the past 5 years, the company’s revenue has grown -3.9%, while the company’s earnings per share has grown -24.2%. With an institutional ownership near 65.8%, it carries an earnings per share ratio of -0.07.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.